One patient with t(1;11)(p32;q23) was reclassified as having AML with KMT2A rearrangement (AML-KMT2A) using the 2022 WHO criteria and AML with other KMT2A rearrangements using the ICC. This evidence concerns the gene KMT2A and intrahepatic cholangiocarcinoma.